A study looking at individual and targeted radiotherapy for non small cell lung cancer

Coronavirus (COVID-19)

We know that this is an especially worrying time for people with cancer and their family and friends. We have separate information about coronavirus and cancer. Please read that information alongside this page. We will update that information as guidance changes.

Read about coronavirus and cancer

Cancer type:

Lung cancer
Non small cell lung cancer

Status:

Results

Phase:

Other

This study looked at a more individual and targeted way of having radiotherapy to treat non small cell lung cancer. It was for people who had lung cancer that couldn’t be removed with surgery. 

Cancer Research UK supported this study.

More about this trial

When doctors can’t remove non small cell lung cancer with surgery, they generally treat it with radiotherapy with or without chemotherapy.
 
Intensity modulated radiotherapy (IMRT) is a type of radiotherapy that doctors can use to target the cancer better. Using IMRT doctors can give a higher dose of radiotherapy to the cancer while giving as little as possible to nearby organs. 
 
The researchers used IMRT and also worked out the dose of radiotherapy for each person individually. 
 
In the study most patients had an increased dose of radiotherapy.
 
About a month after completing chemotherapy everyone had radiotherapy twice a day.
 
The aims of this study were to find out:
  • if it was practical to give an individual targeted dose of radiotherapy 
  • what the side effects were 
  • if this treatment stopped lung cancer from continuing to grow or coming back 
  • if the treatment helped people with lung cancer live longer

Summary of results

The study team found it was possible to give an individual increased targeted dose of radiotherapy.
 
The radiotherapy dose for each person was to be higher than the standard dose Open a glossary item of radiotherapy used for non small cell lung cancer. 
 
Of the 37 people who took part:
  • 2 people had standard radiotherapy instead of the targeted radiotherapy, this was due to the size of their cancer
  • 14 people were able to have the highest dose of radiotherapy
  • 1 person didn’t complete their radiotherapy because their cancer continued to grow
After an average follow up of just over a year, 20 people were still alive. 
 
The team looked at side effects that happened during the radiotherapy and for 4 months afterwards (short term side effects). These included:
  • a cough
  • difficulty swallowing
  • shortness of breath
  • inflammation of the food pipe 
  • skin problems at the treatment area
They also looked at side effects that continued on 4 months after radiotherapy (long term side effects). These included:
  • a cough
  • difficulty swallowing
  • shortness of breath
The team concluded an individual targeted dose of radiotherapy to treat non small cell lung cancer was possible. And the side effects weren’t too bad. A trial called ADSCaN is comparing different ways of giving an increased dose of radiotherapy to the standard ways of giving radiotherapy for non small cell lung cancer. 
 
We have based this summary on information from the research team. The information they sent us has been reviewed by independent specialists (peer reviewed Open a glossary item) but may not have been published in a medical journal.  The figures we quote above were provided by the research team. We have not analysed the data ourselves.

Recruitment start:

Recruitment end:

How to join a clinical trial

Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Chief Investigator

Professor Corinne Faivre-Finn

Supported by

British Lung Foundation
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
The Christie NHS Foundation Trust

Questions about cancer? Contact our information nurses

Freephone 0808 800 4040

Last review date

CRUK internal database number:

10076

Please note - unless we state otherwise in the summary, you need to talk to your doctor about joining a trial.

Around 1 in 5 people take part in clinical trials

3 phases of trials

Around 1 in 5 people diagnosed with cancer in the UK take part in a clinical trial.

Last reviewed:

Rate this page:

Currently rated: 3.3 out of 5 based on 3 votes
Thank you!
We've recently made some changes to the site, tell us what you think